May 2, 2022 Delivered via EmailRetention Agreement • May 5th, 2022 • SpringWorks Therapeutics, Inc. • Biological products, (no disgnostic substances)
May 2, 2022 Delivered via Email Michael Burgess, M.B.Ch.B., Ph.D. Re: Retention Agreement Dear Dr. Burgess:SpringWorks Therapeutics, Inc. • May 5th, 2022 • Biological products, (no disgnostic substances)
This letter (the “Agreement”) confirms the details of our recent conversation. As we discussed, at this time, in light of the critical milestones anticipated for our R&D organization during 2022, SpringWorks Therapeutics, Inc. (the “Company”) considers it to be in the best interests of the Company to provide further incentives to you to remain employed with the Company and has determined that appropriate steps should be taken to reinforce and encourage your continued attention and dedication to your duties and responsibilities. Accordingly, the Company is pleased to offer you the opportunity to receive certain Retention Opportunities (as defined below), subject to the terms and conditions set forth herein:
